Removing B2m with Nanobodies

Among those on dialysis, a build up in the blood of Beta-2 microglobulin (B2m) is responsible for potentially crippling dialysis-related amyloidosis (DRA). Nanobodies are functional antibody fragments—and, used in a resin, they captured 17 times more B2m than in earlier studies, without affecting other blood proteins. Even better, the resin can be regenerated and used again. One day, this approach may be combined with dialysis to improve treatments.

Read the full article » | Posted 03-16-2020

Related Articles

• Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
• FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026
• Drs. Monica Farcus and Jeffrey Perl Win the Mitchell Award for Health System Innovation Posted 01-16-2026
• Nephrodite Wins FDA Breakthrough Device Designation for “Holly” Posted 01-16-2026